The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease
about
Aspirin-sensitive asthma and upper airway diseasesManagement options for patients with aspirin and nonsteroidal antiinflammatory drug sensitivityAspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the futureAspirin-exacerbated respiratory disease: evaluation and management.Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease.Aspirin-exacerbated asthma.A retrospective study of the clinical benefit from acetylsalicylic acid desensitization in patients with nasal polyposis and asthma.A paragonimiasis patient with allergic reaction to praziquantel and resistance to triclabendazole: successful treatment after desensitization to praziquantel.Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory diseaseUtility of low-dose oral aspirin challenges for diagnosis of aspirin-exacerbated respiratory disease.Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes.Nonallergic drug hypersensitivity reactions.Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations.Automated identification of an aspirin-exacerbated respiratory disease cohort.Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics.Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist.Identification of phenotypic clusters of nonsteroidal anti-inflammatory drugs exacerbated respiratory disease.Clinical course of patients with aspirin-exacerbated respiratory disease: can we predict the prognosis?
P2860
Q27023928-C1558C12-62AF-4D45-A093-EE1679D1A527Q28217965-D5E678A8-7DE9-4192-AFF9-175F1A0E4D82Q30238776-34D49071-414F-48ED-B8BC-88902B68C13CQ30477625-E42BF1B4-3BBB-4113-B1B7-BC19CF47E27EQ33693274-3A41F6F5-ACE5-4880-ADB3-B31F445DB49AQ33846722-67E7742E-9395-4B1D-8D3D-BF80C2B4AA88Q34707972-507DF7C5-4AEB-4590-86C8-727E14A31A5AQ34717717-1854EF59-548A-494C-92A6-C89DEB263606Q35589545-5B65C5C4-51FE-4B24-90C5-5FF1D749AA45Q36782772-0B1FC059-D97C-468D-9698-05068219E6C5Q37240446-67E150B6-87A7-4C10-B147-1F233AA29808Q38029476-7DA1A1CE-F486-4F04-8C70-7B84C99D205EQ38915358-729C5A07-5756-49F5-B73F-82B70B20EC92Q38938746-AB5BF69E-030F-43B7-B607-ED8B22154089Q39383738-386CCA01-E873-489A-8E78-99224BF7A856Q39573055-1533C3BE-E375-46FD-A559-24966FF360CBQ47958695-54613C4A-024D-47F7-8D93-C447EEB6B962Q53291503-1CA4EB86-33B9-4031-86E0-34D29BA63103
P2860
The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The blocking effect of essenti ...... xacerbated respiratory disease
@ast
The blocking effect of essenti ...... xacerbated respiratory disease
@en
The blocking effect of essenti ...... xacerbated respiratory disease
@nl
type
label
The blocking effect of essenti ...... xacerbated respiratory disease
@ast
The blocking effect of essenti ...... xacerbated respiratory disease
@en
The blocking effect of essenti ...... xacerbated respiratory disease
@nl
prefLabel
The blocking effect of essenti ...... xacerbated respiratory disease
@ast
The blocking effect of essenti ...... xacerbated respiratory disease
@en
The blocking effect of essenti ...... xacerbated respiratory disease
@nl
P2093
P1476
The blocking effect of essenti ...... xacerbated respiratory disease
@en
P2093
Andrew A White
Donald D Stevenson
Ronald A Simon
P356
10.1016/S1081-1206(10)61150-7
P407
P577
2005-10-01T00:00:00Z